中国生物工程杂志

［1］ Samarajiwa S A, Wilson W, Hertzog P J.Type I interferons: Genetics and structure, in: A. Meager The Interferons.Weinheim: WileyVCH,2006.334. 
［2］ Kotenko SV, Gal1agber G, Baurin W, et al. IFNλs mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Inmmnol, 2003, 4(1):6977. 
［3］ Sheppard P, Kindsvogel W, Xu W, et al. IL28, IL29 and their class II cytokine receptor IL28R. Nature Immunol, 2003, 4(1):6368. 
［4］ Lasfar A, LewisAntes, Kotenko S V, et al. Characterization of the mouse IFNlambda ligandreceptor system: IFNlambdas exhibit antitumor activity against B16 melanoma, Cancer Res,2006,66(8):44684477. 
［5］ Chen Q, Carroll H P, Gadina M. The newest interleukins:recent additions to the evergrowing cytokine family. Vitam Horm, 2006,74:207228. 
［6］ Dumoutier L, Renauld J C. Viral and cellular intedeukin10(IL10)related cytokines: from structures to functions. Eur Cytokine New, 2002,13(1):515. 
［7］ Berghall H, Siren J, Sarkar D, et al. The interferoninducible RNA helicase is involved in measles virusinduced expression of antiviral cytokines. Microbes Infect, 2006,8(8):21382144. 
［8］ Brand S, Beigel F, Olszak T, et al. IL28A and IL29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL28A expression. Am J Physiol Gastrointest Liver Physiol, 2005,289(5):960968. 
［9］ Siren J, Pirhonen J, Julkunen I, et al. IFNα regulates TLRdependent gene expression of IFNα, IFNβ, IL28, and IL29. J. Immunol. 2005,174(4):19321937. 
［10］ Coccia E M, Severa M, Giacomini E,et al. Viral infection and Tolllike receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocytederived dendritic cells. Eur J Immunol, 2004,34(3):796805. 
［11］ Osterlund P, Veckman V, Siren J, et al. Gene expression and antiviral activity of α/β interferons and interleukin29 in virusinfected human myeloid dendriticcells. J Virol,2005,79(15):96089617. 
［12］ Spann K M, Tran K C, Chi B, et al. Suppression of the induction of α, β, and λ interferons by the NS1 andNS2 proteins of human respiratory syncytial virus in human epithelialcells and macrophages. J Virol, 2004,78(8):43634369. 
［13］ Kotenko S V. The family of ILl0related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev, 2002,13(3):223240. 
［14］ Renanld J C. ClassⅡcytokine receptors and their ligands: key antiviral and inflammatory modulators. Nature Rev Immunol,2003, 3(8):667676. 
［15］ Uze G, Monneron D. IL28 and IL29: Newcomers to the interferon family. Biochimie, 2007,89(67):729734. 
［16］ Witte K, Gruetz G,Volk H D,et al.Despite IFNλ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implica tions for therapeutic applications of these cytokines. Genes and Immun, 2009，10(8):702714. 
［17］ Vilcek J. Novel interferons. Nature Imnmnol, 2003, 4(1): 89. 
［18］ Dumoutier L, Tounsi A, Michiels T, et al. Role of interleukin IL28 receptor tyrosine residues for antival and antiproliferative activity of IFNλ1/interferonλ1. J Bio Chem, 2004, 279(31): 3226932274. 
［19］ Dumoutier L, Lejeune D, Hor S, et al. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J, 2003, 370(pt2):391396. 
［20］ Meager A, Visvalingam K, Diger P, et al. Biological activity of interleukins28 and29: Comparison with type I interferons. Cytokine, 2005, 31(2):109118. 
［21］ Jordan WJ, Eskdale J, Srinivas S, et al. Human interferon lambda1 (IFNλ1) modulates the Th1/Th2 response,Genes and Immunity,2007,8(3):254261. 
［22］ Robek M D, Boyd B S, Chisari F V. Lambda interferon inhibits hepatitis B and C virus replication. J Virol, 2005,79(6):38513854. 
［23］ Andrew J M, Mitchell L, Shiffman M L, et al. Phase 1b doseranging study of 4 weeks of PEGInterferon (IFN) Lambda (PEGrIL29) in Combination with Ribavirin (RBV) in Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection AASLD. The Liver Meeting in Boston, MA, October 30  November 3, 2009. 
［24］ Li WA. Regulation of apoptosis by type III interferons. Cell Prolif, 2008,41(6):960979. 
［25］ Numasaki M, Tagawa M, Iwata F, et al. IL28 elicits antitumor responses against murine fibrosarcoma. J Immunol, 2007,178(8):50865098. 
［26］ Sato A,Ohtsuki M,Hata M, et al. Antitumor activity of IFNλ in murine tumor models the journal of immunology,2006, 176(12):76867694. 
［27］ Mennechet F J, Uzé G. Interferonlambdatreated dendritic cells specifically induce proliferation of FOXP3expressing suppressor T cells. Blood, 2006, 107(11):44174423. 
［28］ Maher S G, Sheikh F,Scarzello A J, et al. IFNα and IFNλ differ in their antiproliferative effects and uration of JAK/STAT signaling activity,Cancer Biol Ther, 2008,7(7):11091115. 
［29］ Zitzmann K, Brand S, Baehs S, et al. Novel interferonλs induce antiproliferative effects in neuroendocrine tumor cells. Biochemical and Biophysical Research Communications, 2006,344(4):13341341. 
［30］ Li Q, Kawamura K, Ma G, et al. Interferonλ induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces antitumour effects in combination with anticancer agents, Eur J Cancer, 2010,46(1):180190.